Introduction
============

As a common neurodegenerative movement disorder, Parkinson's disease (PD) is characterized by slowness of movement, rigidity, postural instability, and resting tremor.[@b1-ndt-14-3219] These clinical manifestations were resulted from progressive loss of dopamine producing neurons in the substantia nigra pars compacta and widespread intracellular aggregation of the protein alpha-synuclein, the principal component of the pathological hallmark of PD, Lewy bodies.[@b2-ndt-14-3219] Despite the increasing efforts for exploring the etiology of PD, the exact pathology of PD was not fully defined.

Long noncoding RNAs (lncRNAs) are non-protein-coding transcripts over 200 nucleotides bases long. Recently, accumulated evidences have emphasized the importance of lncRNAs in brain function and central nervous system (CNS) disorders.[@b2-ndt-14-3219]--[@b5-ndt-14-3219] The functions of lncRNAs span from regulating brain evolution and neural development[@b3-ndt-14-3219] to mediating behavioral and cognitive processes.[@b4-ndt-14-3219],[@b5-ndt-14-3219] Moreover, lncRNAs were reported to regulate the transcription of nearby genes with *cis*-regulatory effects. Up to date, several lncRNAs such as NEAT1, SNHG1, MAPT-AS1, and HOTAIR have been demonstrated to play roles in PD.[@b6-ndt-14-3219]--[@b9-ndt-14-3219] Yanxia Fan et al reported differentially expressed genes, *ZFAND4*, *SRMS*, *UBL4B*, *PVALB*, *DIRAS1*, *PDP2*, *LRCH1*, and *MYL4* were potential biomarkers associated with progression rate of PD.[@b10-ndt-14-3219] The study of Jieshan Chi et al suggested that five significantly down-regulated mRNAs (*MAPK8*, *CDC42*, *NDUFS1*, *COX4I1*, and *SDHC*) and three significantly down-regulated miRNAs (miR-126-5p, miR-19-3p, and miR-29a-3p), were potentially useful diagnostic markers in clinic.[@b11-ndt-14-3219]

In this present study, we identified the differentially expressed lncRNAs (DElncRNAs) and mRNAs (DEmRNAs) between PD and normal controls by RNA sequencing and bioinformatics analysis. Identification of *cis* nearby targeted DEmRNAs of DElncRNAs and functional annotation of DEmRNAs would facilitate the exploration of the biological functions of DElncRNAs in PD. This study will provide new clues for understanding the pathogenesis and developing potential biomarkers of PD.

Materials and methods
=====================

Patients and samples
--------------------

Three patients with PD and three normal controls were enrolled in the present study from July 12, 2017, to August 29, 2017. PD was diagnosed based on MDS clinical diagnostic criteria.[@b12-ndt-14-3219] Patients with other long-term chronic disease and serious disease were excluded. The details of these patients were as follows: a 54-year-old male with 3 years of slow movement and jitter of left upper limb at Hoehn-Yahr stage 1.5; a 60-year-old male with \>4 years of slow movement and progressive hand shaking at Hoehn-Yahr stage 2.5, and a 52-year-old male with \>2 years of slow movement and hand shaking at Hoehn-Yahr stage 2.0, respectively. All these patients have no family history of PD. Three normal controls were 65-, 54-, and 53-year old healthy males. All individuals provided signed informed consent for use of their samples in this present study. The present study has been approved by the Ethics Committee of the First People's Hospital of Nantong.

From each participant, a 2.5 mL peripheral whole blood was collected in PAXgene^®^ RNA blood tubes (PreAnalytiX GmbH, Hombrechtikon, Switzerland) and stored at −80°C prior to processing.

RNA isolation and sequencing
----------------------------

With PAXgene blood RNA kit (PreAnalytiX GmbH, Hombrechtikon, Switzerland), RNA isolation was conducted on the manufacturer's protocol. By using Nanodrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA), the concentration and purity of RNA were assessed. The integrity of RNA was assessed via a 2% agarose gel. Agilent 2100 bioanalyzer was used to obtain the RIN values. The criteria for cDNA library construction were as follows: 1) Total RNA \>5 µg; 2) concentration of RNA ≥200 ng/mL; 3) OD 260/280 value 1.8--2.2.

Ribosomal RNA was removed with Ribo-Zero Magnetic kit (EpiCentre, Madison, WI, USA). Then, RNA was purified and fragmented into fragments with 140--160 nt. The first cDNA strand was synthesized via RNA fragments primed with random hexamer primers. The second cDNA strand was synthesized with dUTP instead of dTTP. End repair was conducted by using End Repair Enzyme mix (NEB, Ipswich, MA, USA). Subsequently, 3′ end adenylation and adapter ligation were performed. After digesting the second cDNA strand with UNG enzyme (Illumina, Inc., San Diego, CA, USA), PCR was performed for 15 cycles to amplify the libraries. Purification and recovery of libraries were performed by using commercial magnetic beads. Sequencing was performed on the Illumina Hiseq X-ten platform (Illumina, Inc.).

Quality control of raw sequence and mapping of clean reads
----------------------------------------------------------

By using Base Calling version 0.11.4 (<http://www.bioin-formatics.babraham.ac.uk/projects/fastqc/>),[@b35-ndt-14-3219] the FASTQ sequence data were obtained from the RNA-sequencing data. Reads with low quality (adaptor sequences, sequences with a quality score \<20, and sequences with an N base rate of raw reads \>10%) were removed with Cutadapt version 1.9.1 (<https://cutadapt.readthedocs.io/en/stable/>)[@b36-ndt-14-3219] to obtain the clean reads.

Identification of DEmRNAs and DElncRNAs in PD compared with normal controls
---------------------------------------------------------------------------

TopHat release 2.2.1 (<http://tophat.cbcb.umd.edu/>)[@b37-ndt-14-3219] was used to align the clean reads with the human reference genome, Ensemble GRCh38.p7 (<ftp://ftp.ncbi.nlm.nih.gov/genomes/Homo_sapiens>).[@b38-ndt-14-3219] With Cuffquant version 2.2.1 (<http://cufflinks.cbcb.umd.edu/>),[@b39-ndt-14-3219] expressions of mRNAs and lncRNAs were normalized and outputted. Fragments per Kilobase of exon per million fragments mapped (FPKM) was used to determine the transcription abundance of lncRNAs and mRNAs. With Cuffdiff version 2.2.1 (<http://cufflinks.cbcb.umd.edu/>),[@b39-ndt-14-3219] FPKM of lncRNAs and mRNAs were calculated. Both DEmRNAs and DElncRNAs were obtained with DESeq2 (<http://bioconductor.org/packages/DESeq2/>)[@b40-ndt-14-3219] in R version 3.3.3 with *P*-value \<0.05. Hierarchical clustering analyses of DElncRNAs and DEmRNAs were conducted by using R package "pheatmap".

Functional annotation of DEmRNAs between PD and normal control
--------------------------------------------------------------

Functional annotation, including Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the DEmRNAs between PD and normal control, was performed using the GeneCoDis3 tool (<http://genecodis.cnb.csic.es/analysis>).[@b41-ndt-14-3219] False discovery rate (FDR) \<0.05 was set as the cutoff for significance.

Protein--protein interaction (PPI) network construction
-------------------------------------------------------

With the Biological General Repository for Interaction Datasets (BioGrid, <http://www.uniprot.org/database/DB-0184>),[@b42-ndt-14-3219] top 100 up- and downregulated DEmRNAs were scanned. PPI network was then constructed using Cytoscape software (version 3.3.0, <http://www.cytoscape.org>)[@b43-ndt-14-3219] in order to further explore the biological functions of the DEmRNAs.

*Cis* nearby targeted DEmRNAs of the DElncRNAs
----------------------------------------------

To obtain the targeted DEmRNAs of DElncRNAs with *cis*-regulatory effects, DEmRNAs transcribed within a 100 kb window upstream or downstream of DElncRNAs were searched, which were defined as *cis* nearby targeted DEmRNAs of DElncRNAs.

Validation in the GEO dataset
-----------------------------

GSE57475 and GSE68719 datasets were downloaded from the Gene Expression Omnibus (GEO; <https://www.ncbi.nlm.nih.gov/geo/>),[@b44-ndt-14-3219] which consisted of 49 patients with PD and 93 normal controls, and 29 patients with PD and 44 normal controls, respectively. The dataset GSE57475 examined the blood sample and GSE68719 examined brain tissue, which were all from USA. The expression patterns of selected DEmRNAs were validated with GSE57475 and GSE68719 datasets.

Results
=======

RNA-sequencing data
-------------------

Total RNA isolated from each blood sample met the criteria for cDNA library construction and RNA sequencing. After trimming of the raw reads, 6.7 × 10^7^ clean reads were obtained from each blood sample from patients with PD and normal controls. The mapping ratio was calculated following clean reads of each sample aligned to the human reference genome (GRCh38.p7). Mapping ratio of each sample was \>84%.

DEmRNAs and DElncRNAs between PD and normal controls
----------------------------------------------------

A total of 857 DEmRNAs (304 upregulated and 553 downregulated DEmRNAs) and 77 DElncRNAs (38 upregulated and 39 downregulated DElncRNAs) between PD and normal controls were identified. The top ten up- and downregulated DElncRNAs and DEmRNAs between PD and normal controls are summarized in [Tables 1](#t1-ndt-14-3219){ref-type="table"} and [2](#t2-ndt-14-3219){ref-type="table"}, respectively. Hierarchical clustering analysis of DElncRNAs and top 100 DEmRNAs is displayed in [Figure 1A and B](#f1-ndt-14-3219){ref-type="fig"}, respectively. Furthermore, all these DElncRNAs were distributed in all chromosomes (chr.), with the exception of chr.15 and chr.16, and DEmRNAs were widely distributed in all chromosomes ([Figure 1C](#f1-ndt-14-3219){ref-type="fig"}).

Functional annotation
---------------------

Blood coagulation (FDR =4.11E−11), platelet activation (FDR =2.55E−09), plasma membrane (FDR =1.48E−11), protein binding (FDR =2.40E−30), and cytoplasm (FDR =2.54E−36) are significantly enriched GO terms in PD ([Figure 2A--C](#f2-ndt-14-3219){ref-type="fig"}). Natural killer cell-mediated cytotoxicity (FDR =2.36E−08), pathways in cancer (FDR =6.82E--06), and protein processing in endoplasmic reticulum (FDR =1.54E−05) are three significantly enriched KEGG pathways in PD ([Figure 2D](#f2-ndt-14-3219){ref-type="fig"}).

PPI network
-----------

The PD-specific PPI network was consisted of 186 nodes and 194 edges. ERBB2 (degree =13), HSPB1 (degree =13), and MYC (degree =11) were three hub proteins of PD-specific PPI network ([Figure 3](#f3-ndt-14-3219){ref-type="fig"}).

*Cis* nearby targeted DEmRNAs of DElncRNAs
------------------------------------------

A total of 39 DElncRNAs nearby targeted DEmRNA pairs were obtained which was consisted of 28 DElncRNAs and 36 DEmRNAs. LOC105378701-*TAL1*, LOC102724104-*C X 3 C R 1*, L O C 1 0 5 3 7 5 0 5 6 - *T R E M L 1/T R E M L 4*, LOC105379392-*ANK1*, and LOC101928100-*KLRK1*/*KLRD1* interactions were identified DElncRNAs nearby targeted DEmRNA pairs in PD ([Table 3](#t3-ndt-14-3219){ref-type="table"}).

Validation in the GEO dataset
-----------------------------

The expression patterns of six DEmRNAs including TAL bHLH transcription factor 1 (*TAL1*), triggering receptor expressed on myeloid cells like 1 (*TREML1*), triggering receptor expressed on myeloid cells like 4 (*TREML4*), erb-b2 receptor tyrosine kinase 2 (*ERBB2*), chemokine (C-X3-C) receptor 1 (*CX3CR1*) and ankyrin 1 (*ANK1*) were verified using GSE57475 dataset. As shown in [Figure 4](#f4-ndt-14-3219){ref-type="fig"}, *TAL1*, *TREML1*, *TREML4*, and *ANK1* were downregulated while *ERBB2* and *CX3CR1* were upregulated in PD compared with normal controls, which were consistent with our RNA-sequencing results ([Figure 4](#f4-ndt-14-3219){ref-type="fig"}).

In GSE68719 dataset, the expression patterns of *ERBB2*, *CX3CR1*, and *ANK1* were similar to that in GSE57475, while for *TAL1* and *TREML1*, it displayed the opposite. *TREML4* was not found in GSE68719. The result may be due to the difference of the tissue types between GSE57475 and GSE68719. We further determined the expression of killer cell lectin like receptor D1 (*KLRD1*), a DEmRNA between PD and normal controls, and found that its expression status was consistent with our RNA-sequencing results ([Figure 5](#f5-ndt-14-3219){ref-type="fig"}).

Discussion
==========

Increasing evidences have indicated that lncRNAs play important roles in the pathogenesis of PD.[@b6-ndt-14-3219]--[@b9-ndt-14-3219] This present study identified abundant lncRNAs that were differentially expressed between PD and normal controls.

JHDM1D antisense 1 (JHDM1D-AS1) was an lncRNA that arises from the antisense strand of JHDM1D and was downregulated in PD in this present study. In in vitro and in vivo experiments, JHDM1D-AS1 was found to be upregulated in cancer cells and tumor tissues under nutrient starvation, which promotes tumorigenesis by upregulating angiogenesis and triggering inflammation.[@b13-ndt-14-3219] Accumulated evidence indicated that neuroinflammation plays key roles in the pathogenesis of neurodegenerative diseases.[@b14-ndt-14-3219],[@b15-ndt-14-3219] Angiogenesis has been found in various neurodegenerative diseases such as Alzheimer's disease (AD)[@b16-ndt-14-3219] and PD[@b1-ndt-14-3219] which was speculated to make a contribution for neuroinflammation by failing to protect the parenchyma from peripheral immune cells and inflammatory or toxic factors in the peripheral circulation.[@b1-ndt-14-3219] Hence, we made a hypothesis that JHDM1D-AS1 might be involved with the process of PD by regulating angiogenesis and neuroinflammation. Further experiments are needed to explore the precise role of JHDM1D-AS1 in PD.

However, the biological functions of most identified DElncRNAs between PD and normal control remain unclear. Previous studies indicated that lncRNAs might regulate the expression of their nearby genes by *cis*-regulatory effects.[@b17-ndt-14-3219] To further research the functions of DElncRNAs in PD, we searched the DEmRNAs transcribed within a 100 kb window upstream or downstream of DElncRNAs which served as *cis* nearby targeted DEmRNAs of DElncRNAs.

In this present study, downregulated *TAL1* was found in PD compared with normal controls, and interacted with seven DEmRNAs of PD. Microglia is essential for innate neuroimmune function and CNS homeostasis, and plays crucial roles in neurodegeneration and brain aging.[@b18-ndt-14-3219] *TAL1* is a transcription factor that involves with microglial aging.[@b19-ndt-14-3219] Hence, *TAL1* was speculated to play key roles in initiation of PD by regulating many key DEmRNAs between PD and normal controls.[@b20-ndt-14-3219] Additionally, TAL1 was identified to be a nearby targeted DEmRNA of LOC105378701, which suggested that LOC105378701 might involve with PD by regulating the expression of *TAL1* with *cis* effect.

CX3CR1 is a specific receptor of fractalkine (also called *CX3CL1*) that is exclusively expressed in micro-glia in the CNS.[@b21-ndt-14-3219] Fractalkine/*CX3CR1* signaling plays an inhibitory role in control of microglial inflammatory response.[@b22-ndt-14-3219] Knockout of *CX3CR1* was found to exacerbate inflammation and neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxin model of PD.[@b23-ndt-14-3219] Sun et al demonstrated for the first time that *CX3CR1* is involved in the neuroinflammatory process in 1-methyl-4-phenylpyridiniumion (MPP+) rat model of PD.[@b24-ndt-14-3219] Both the RNA-sequencing results and our gene expression validation results found that *CX3CR1* was upregulated in PD compared with normal control, which emphasized the importance of CX3CR1 in PD. Further research is needed to explore its precise role in PD. Moreover, *CX3CR1* was a nearby targeted gene of LOC102724104, which suggested that LOC102724104 might be a potential regulator of PD by regulating *CX3CR1*.

*ERBB2*, also known as human epidermal growth factor receptor 2 (*HER2*), a receptor tyrosine kinase, was originally identified based on its role in cancer research. Wang et al first suggested a link between PD and *HER2* polymorphism, and they indicated that different signals or potency of the kinase activities resulting from the Ala1170Pro allele of *HER2* may be associated with vulnerability to stress on dopaminergic neurons in PD.[@b25-ndt-14-3219] In this present study, *ERBB2* was a hub protein of PD-specific PPI network. Moreover, *ERBB2* was a nearby targeted gene of LOC105372578, which suggested that LOC105372578 might be a potential regulator of PD by regulating *ERBB2*.

AD is also a type of neurodegenerative disease. We identified three AD-regulated genes that were differentially expressed between PD and normal control as well.

*ANK1* is a known susceptibility gene for type 2 diabetes which was recognized to own some similarities with AD.[@b26-ndt-14-3219] Aberrant methylation and expression of *ANK1* were found in AD.[@b27-ndt-14-3219],[@b28-ndt-14-3219] Cortical-specific hypermethylation of *ANK1* was robustly associated with AD-related neuropathology.[@b28-ndt-14-3219] Lunnon et al speculated that the brain-expressed *ANK1* protein could be associated with pathology of AD by its function on compartmentalization of the plasma membrane.[@b28-ndt-14-3219]

The triggering receptors expressed on myeloid (TREM) family is known to play a key role in modulating inflammation in the innate immune response.[@b29-ndt-14-3219] Both *TREML1* and *TREML4* were reported to be plausible risk genes of AD.[@b30-ndt-14-3219] Reliable expression of *TREML1* was found in both cerebellum and temporal cortex of brain.[@b30-ndt-14-3219] Variant of *TREM1* (rs6910730) was associated with increased AD pathology burden and increased rate of cognitive decline, independently.[@b31-ndt-14-3219] Moreover, *TREML1* was reported to be involved with promoting vascular homeostasis and neuroinflammation that was speculated to be a potential mediator of neuronal protection and injury in AD and possibly other CNS diseases.[@b30-ndt-14-3219]

To the best of our knowledge, we first found the downregulation of *ANK1*, *TREML1*, and *TREML4* in PD compared with normal controls, which might involve with PD as well. Both *TREML1* and *TREML4* were nearby targeted genes of LOC105375056, and ANK1 was a nearby targeted gene of LOC105379392, which suggested that LOC105375056 and LOC105379392 and their interactions with *TREML1*/*TREML4* or *ANK1* might implicate in PD.

In addition, several studies of the familial PD genes had emphasized the importance of RNA metabolism, particularly mRNA translation, in the disease process. Bingwei Lu et al had indicated that several familial PD genes, including *LRRK2*, *PINK1*, *Parkin*, and *eIF4G1*, have been shown to interact with components of the translation initiation machinery or interact with modulators of the translation initiation process, such as miRNAs and the mTORC1 signaling pathway.[@b32-ndt-14-3219]--[@b34-ndt-14-3219] In the future, the research on RNA metabolism in PD needs to be carried more.

According to the KEGG enrichment analysis, natural killer cell-mediated cytotoxicity was a significantly enriched pathway in PD. *KLRD1* and killer cell lectin like receptor K1 (*KLRK1*) were the two DEmRNAs enriched in the pathway of natural killer cell-mediated cytotoxicity, and *KLRD1* and *KLRK1* were also the nearby targeted DEmRNAs of LOC101928100. These findings suggested the potential roles of LOC101928100 and its interactions with *KLRK1/KLRD1* in PD.

Conclusion
==========

Our data showed that an abundant of novel DElncRNAs may be associated with the pathology of PD. lncRNA interaction pairs of JHDM1D-AS1, LOC105378701-*TAL1*, LOC102724104-*CX3CR1*, LOC105375056-*TREML1*/*TREML4*, LOC105379392-*ANK1*, and LOC101928100-*KLRK1*/*KLRD1* might involve with PD. Their detailed roles in PD need to be clarified in our future work.

Limitations
===========

The sample size for RNA sequencing in this study was small. Although the validation based on GSE57475 and GSE68719 suggested that our RNA-sequencing results were generally convincing, studies with larger sample size are needed to confirm this conclusion.
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![DElncRNAs and DEmRNAs between PD and normal controls.\
**Notes:** (**A**, **B**) Hierarchical clustering results of DElncRNAs and top 100 DEmRNAs between PD and normal controls, respectively. Row and column represent DElncRNAs/DEmRNAs and tissue samples, respectively. The color scale represents the expression levels. (**C**) Distribution of DElncRNAs and DEmRNAs on chromosomes. The outer layer cycle was the chromosome map of the human genome hg19 (GRCh37). The red and blue inner layer represents the distribution of up- and downregulated DEmRNAs on different chromosomes, respectively. The pink and light blue inner layer represents the distribution of up- and downregulated DElncRNAs on different chromosome, respectively.\
**Abbreviations:** DElncRNAs, differentially expressed long noncoding RNAs; DEmRNAs, differentially expressed micro RNAs; PD, Parkinson's disease.](ndt-14-3219Fig1){#f1-ndt-14-3219}

![Significantly enriched GO terms and KEGG pathways of DEmRNAs between PD and normal controls.\
**Notes:** (**A**) BP, (**B**) CC, (**C**) MF, and (**D**) KEGG pathways. The x-axis shows counts of DEmRNAs enriched in GO terms or KEGG pathways and the y-axis shows GO terms or KEGG pathways. The color scale represented −log FDR.\
**Abbreviations:** BP, biological process; CC, cellular component; DEmRNAs, differentially expressed mRNAs; FDR, false discovery rate; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function.](ndt-14-3219Fig2){#f2-ndt-14-3219}

![PD-specific PPI network.\
**Notes:** The red and blue ellipses represent proteins encoded by up- and downregulated DEmRNAs between PD and normal control. Ellipses with black and blue border are DEmRNAs derived from top ten down- and upregulated DEmRNAs between PD and normal control.\
**Abbreviations:** DEmRNAs, differentially expressed mRNAs; PD, Parkinson's disease; PPI, protein--protein interaction.](ndt-14-3219Fig3){#f3-ndt-14-3219}

![Validation of selected DEmRNAs in GSE57475.\
**Notes:** The x-axis shows PD and normal control groups and the y-axis shows relative expression levels. (**A**) TAL1; (**B**) TREML1; (**C**) TREML4; (**D**) ERBB2; (**E**) CX3CR1; (**F**) ANK1. The circles represent outliers.\
**Abbreviations:** DEmRNAs, differentially expressed micro RNAs; PD, Parkinson's disease.](ndt-14-3219Fig4){#f4-ndt-14-3219}

###### 

Validation of selected DEmRNAs in GSE68719.

**Notes:** The x-axis shows PD and normal control groups and the y-axis shows relative expression levels. (**A**) TAL1; (**B**) TREML1; (**C**) ERBB2; (**D**) CX3CR1; (**E**) ANK1; (**F**) KLRD1. The circles represent outliers. \**P* \< 0.05 and \*\**P* \< 0.01.

**Abbreviations:** DEmRNAs, differentially expressed micro RNAs; PD, Parkinson's disease.
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###### 

Top ten up- and downregulated DElncRNAs between PD and normal controls

  DElncRNAs          Log2 fold change   *P*-value   Regulation
  ------------------ ------------------ ----------- ------------
                                                    
  TM4SF19-TCTEX1D2   1.91E+00           7.41E−07    Up
  LOC101927369       1.21E+00           1.37E−04    Up
  LOC102724104       1.04E+00           1.60E−04    Up
  LINC01871          1.11E+00           1.79E−04    Up
  LOC105373420       1.25E+00           9.26E−04    Up
  LOC105371464       7.73E−01           1.94E−03    Up
  LINC00943          9.86E−01           3.50E−03    Up
  LOC105370060       1.09E+00           4.41E−03    Up
  LOC101927012       9.74E−01           5.26E−03    Up
  LOC105372055       9.94E−01           5.88E−03    Up
  LOC102724765       −1.07E+00          1.38E−04    Down
  LOC105369772       −1.34E+00          4.76E−04    Down
  KRT73-AS1          −1.25E+00          5.00E−04    Down
  LOC105379392       −9.44E−01          6.04E−04    Down
  JHDM1D-AS1         −8.08E−01          1.96E−03    Down
  LOC105372185       −1.03E+00          2.02E−03    Down
  LOC105377225       −7.01E−01          2.02E−03    Down
  LOC105378701       −1.18E+00          2.15E−03    Down
  LOC105375056       −1.12E+00          2.34E−03    Down
  LOC105373204       −7.02E−01          3.74E−03    Down

**Abbreviations:** DElncRNAs, differentially expressed long noncoding RNAs; PD, Parkinson's disease.

###### 

Top ten up- and downregulated DEmRNAs between PD and normal controls

  DEmRNAs          Log2 fold change   *P*-value   Regulation
  ---------------- ------------------ ----------- ------------
                                                  
  *NINL*           1.67E+00           6.23E−13    Up
  *GZMB*           1.28E+00           6.70E−11    Up
  *COL6A2*         1.23E+00           1.48E−09    Up
  *GZMH*           1.19E+00           4.64E−09    Up
  *ERBB2*          1.12E+00           5.98E−09    Up
  *FGFBP2*         1.13E+00           1.71E−08    Up
  *GNLY*           1.10E+00           6.61E−08    Up
  *C1orf21*        9.67E−01           7.48E−08    Up
  *APOBEC3B*       1.23E+00           9.63E−08    Up
  *PRSS23*         1.09E+00           1.07E−07    Up
  *LRRN3*          −1.49E+00          4.27E−14    Down
  *KRT73*          −1.72E+00          1.11E−13    Down
  *MYL4*           −1.29E+00          3.20E−13    Down
  *FKBP8*          −1.05E+00          5.03E−11    Down
  *KIAA1324*       −1.43E+00          3.18E−10    Down
  *XK*             −1.08E+00          2.81E−08    Down
  *GNG11*          −1.13E+00          3.12E−08    Down
  *TMEM158*        −1.19E+00          4.10E−07    Down
  *IL6ST*          −6.84E−01          5.64E−07    Down
  *LOC102723750*   −9.81E−01          8.30E−07    Down

**Abbreviations:** DEmRNAs, differentially expressed micro RNAs; PD, Parkinson's disease.

###### 

Nearby targeted DEmRNAs of DElncRNAs between PD and normal controls

  DElncRNAs       Nearby targeted DEmRNAs                                     
  --------------- ------------------------- ----------- --------- ----------- -----------
                                                                              
  CTD-2201I18.1   79891295                  80183665    SERINC5   80111226    80256082
  EPHA1-AS1       143253399                 143623449   EPHA1     143390813   143408892
  EPHA1-AS1       143253399                 143623449   FAM131B   143353399   143382304
  HCG11           26386648                  26627393    BTN3A1    26402237    26415216
  HCG11           26386648                  26627393    BTN3A2    26365158    26453415
  KRT73-AS1       52485588                  52720133    KRT1      52674735    52680407
  KRT73-AS1       52485588                  52720133    KRT72     52585588    52602900
  KRT73-AS1       52485588                  52720133    KRT73     52585588    52620133
  LEF1-AS1        107947544                 108276430   LEF1      108047544   108176430
  LOC101927012    147459993                 147882848   JAKMIP2   147559993   147782848
  LOC101927369    35997885                  36256994    CCL4      36097885    36156994
  LOC101928100    10263768                  10510146    KLRD1     10238384    10329607
  LOC101928100    10263768                  10510146    KLRC4     10407384    10409757
  LOC101928100    10263768                  10510146    KLRK1     10372353    10390054
  LOC101929866    45078476                  45291638    PI3       45174898    45176544
  LOC101929866    45078476                  45291638    SLPI      45230820    45290352
  LOC102724104    39132519                  39363406    CX3CR1    39263493    39281735
  LOC105369772    52525675                  52730770    KRT1      52674735    52680407
  LOC105369772    52525675                  52730770    KRT72     52585588    52602900
  LOC105369772    52525675                  52730770    KRT73     52585588    52620133
  LOC105370556    70420816                  70664742    TTC9      70641786    70675360
  LOC105371464    159700480                 159916257   FCRL6     159800480   159816257
  LOC105372491    560703                    796189      SRXN1     646614      658840
  LOC105372578    24819978                  25032985    CST7      24949229    24959928
  LOC105372716    62683185                  62894281    COL9A3    62817061    62937952
  LOC105372881    207265821                 207473252   CD55      207321471   207360966
  LOC105373943    235394088                 236231800   AGAP1     235494088   236131800
  LOC105374771    64290955                  64525399    LGALSL    64454192    64461383
  LOC105375056    41049096                  41278568    TREML4    41228291    41239386
  LOC105375056    41049096                  41278568    TREML1    41149096    41178568
  LOC105375796    143451962                 143663062   TSTA3     143612617   143618043
  LINC02084       27612180                  27814006    EOMES     27715948    27722715
  LOC105377110    58950175                  61351474    FHIT      59050175    61251474
  LOC105378678    41328211                  41564911    HIVEP3    41506364    42035925
  LOC105378701    47072216                  47277080    STIL      47250138    47314787
  LOC105378701    47072216                  47277080    TAL1      47216289    47232389
  LOC105379392    41553224                  41996762    ANK1      41653224    41896762
  SIRPG-AS1       1529151                   1786516     SIRPG     1629151     1686516
  TMEM9B-AS1      8847200                   9076283     AKIP1     8911116     8933006

**Abbreviations:** DElncRNAs, differentially expressed long noncoding RNAs; DEmRNAs, differentially expressed micro RNAs; PD, Parkinson's disease.
